1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,250 | 1,308 | 22:13 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:06 | Aelis Farma: Combined General Meeting of June 3, 2026: Availability of Preparatory Documents and Participation and Voting Procedures | 275 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 24.04. | Aelis Farma: Availability of the 2025 Universal Registration Document | 315 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 07.04. | Aelis Farma erhält 458.000 Euro für Adipositas-Forschung | 2 | Investing.com Deutsch | ||
| 07.04. | Aelis Farma receives €458,000 grant for obesity research | 1 | Investing.com | ||
| 07.04. | Aelis Farma Awarded a €458k Grant Under France 2030 in Nouvelle-Aquitaine to Support Development of Its Program in Obesity and Associated Metabolic Diseases | 291 | Business Wire | This non-dilutive funding, granted under the Projets d'Avenir Innovation (PAI) scheme, strengthens Aelis Farma's "metabolism" program and validates its innovation potential in a therapeutic area... ► Artikel lesen | |
| 30.03. | Aelis Farma Reports Its 2025 Annual Financial Results and Confirms Its 2026 Outlook | 581 | Business Wire | 2025 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates:
AEF0117: announcement of the final results of the Phase... ► Artikel lesen | |
| AELIS FARMA Aktie jetzt für 0€ handeln | |||||
| 21.03. | Aelis Farma startet Patientenrekrutierung für Studie zu Down-Syndrom-Medikament | 2 | Investing.com Deutsch | ||
| 21.03. | Aelis Farma begins recruiting for Down syndrome drug trial | 2 | Investing.com | ||
| 21.03. | Aelis Farma announces the successful start of the recruitment of the Phase 2B clinical trial with AEF0217 for the treatment of behavioral and cognitive impairments of people with Down syndrome (Trisomy 21) | 732 | Business Wire | AEF0217 is a first-in-class Signalling Specific inhibitor of the CB1 receptor (CB1-SSi) developed as a treatment for impairments in adaptive behaviours and cognition in neurodevelopmental disorders... ► Artikel lesen | |
| 26.01. | Aelis Farma Announces Its 2026 Financial Calendar | 284 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral... ► Artikel lesen | |
| 12.01. | Aelis Farma Receives a Positive Opinion From EMA Pediatric Committee on the Pediatric Investigation Plan for AEF0217 in Down Syndrome | 359 | Business Wire | The EMA's Pediatric Committee (PDCO) has delivered a favorable consensus opinion on the Pediatric Investigational Plan (PIP) of Aelis Farma's first-in-class drug candidate AEF0217 for the treatment... ► Artikel lesen | |
| 02.12.25 | Aelis Farma Obtains Regulatory Approval of the Phase 2B Trial With AEF0217 in People With Down Syndrome | 454 | Business Wire | AEF0217 is a first-in-class CB1 receptor Signalling Specific inhibitor (CB1-SSi) developed as a potential first pharmacological treatment for impairments in adaptive behaviours and cognition... ► Artikel lesen | |
| 25.09.25 | Aelis Farma: Availability of the 2025 Half-Year Financial Report | 409 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 22.09.25 | Aelis Farma Reports 2025 Half-Year Financial Results and Presents Progress and Development Outlook | 589 | Business Wire | The first half of 2025 was marked by: The publication of the final analysis of the pioneering Phase 2b clinical trial in cannabis use disorders (CUD) with the CB1-SSi AEF0117, which further... ► Artikel lesen | |
| 24.06.25 | Aelis Farma: Availability of the Description of the Share Buyback Program | 453 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 27.05.25 | Results of Aelis Farma Combined General Meeting of May 27, 2025 | 484 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,350 | -1,56 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| EVOTEC | 4,540 | -10,63 % | Evotec-Aktie: Explodiert der Kurs jetzt Richtung 10€? | Nachdem der Kurs der Evotec-Aktie zuletzt deutlicher in Bewegung geraten ist, richtet sich der Blick nun auf die aktuellen Unternehmenszahlen und die operative Entwicklung. Der erwartungsgemäße Start... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,760 | +5,17 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| PRAXIS PRECISION MEDICINES | 345,18 | +0,58 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,515 | +8,57 % | Stifel Remains Bullish on Tango Therapeutics (TNGX) | ||
| BIONTECH | 78,95 | -1,07 % | Aktien im Fokus - LPKF Laser: Party bald vorbei? - BioNTech, BVB, Elmos, Rheinmetall und Verbio | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| C4 THERAPEUTICS | 3,690 | +16,40 % | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 117,53 | +8,17 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 65,07 | +8,76 % | Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales | ||
| MINERALYS THERAPEUTICS | 27,010 | -7,69 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | - NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 - - Conference call today at 4:30 p.m. ET - RADNOR, Pa., May 06, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 43,640 | +3,17 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | Phase 1 data update for ELVN-001 expected mid-2026
Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026
Strong balance... ► Artikel lesen | |
| VERA THERAPEUTICS | 39,070 | +6,46 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| CG ONCOLOGY | 74,02 | +2,71 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant... ► Artikel lesen | |
| MODERNA | 43,090 | -5,01 % | JEFFERIES stuft Moderna auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Moderna auf "Hold" mit einem Kursziel von 45 US-Dollar belassen. Andrew Tsai bezog am Dienstag Stellung zur jüngsten Kursstärke... ► Artikel lesen | |
| TYRA BIOSCIENCES | 36,200 | +3,81 % | Tyra Biosciences GAAP EPS of -$0.64 |
AELIS FARMA SAS gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,208 Euro und damit +0,50 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AELIS FARMA SAS finden Sie auf Wallstreet Online.